# Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis

> **NCT04120090** · PHASE3 · UNKNOWN · sponsor: **Beijing Friendship Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Hemophagocytic Lymphohistiocytosis

## Interventions

- **DRUG:** low dose ruxolitinib
- **DRUG:** high dose ruxolitinib

## Key facts

- **NCT ID:** NCT04120090
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-01
- **Primary completion:** 2020-07-01
- **Final completion:** 2020-07-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2019-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04120090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04120090, "Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04120090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*